Amifloxacin (WIN 49375) activity against a well-defined group of gentamicin-resistant gram-negative bacilli was compared with the activity of 11 other antimicrobial agents. For all strains, amifloxacin and norfloxacin were the most active agents, followed by cefotaxime and moxalactam. For Acinetobacter sp. only amifloxacin had an achievable MIC for 90% of the strains. Amifloxacin joins other newly developed DNA gyrase inhibitors as potentially useful agents for infections due to aminoglycoside-resistant gram-negative bacilli.
The proliferation of antibiotic resistance, particularly among gram-negative bacteria, has prompted a continuing search for new agents unaffected by existing mechanisms of resistance. The quinolones are a group of synthetic antimicrobial agents whose prototype, nalidixic acid, was developed over 30 years ago (5, 7, 10) . Because of its poor levels in serum and the apparent ease with which resistance developed, nalidixic acid has remained a second-line agent (5) . Yet the unique antimicrobial action of nalidixic acid-like agents-selective inhibition of DNA gyrase-has remained of interest. Newer DNA gyrase inhibitors have recently been shown to be much more active in vitro than nalidixic acid (1) , and their pharmacokinetics are promising. One new quinolone, amifloxacin (WIN 49375) [6-fluoro-1,4-dihydro-1-(methalamino)-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid] (Fig. 1 706, 1983) . Amifloxacin is active against most facultative and aerobic gram-negative bacteria, including Pseudomonas aeruginosa, but its activity against multiresistant strains has not been studied (8) . For this reason we tested the activity of amifloxacin against a well-defined group of multiresistant gram-negative bacteria.
Amifloxacin Good activity for :efotaxime (MIC50 = 8 jig/ml) and moxalactam (MIC50 = 4 ,ug/ml) was present against half of all strains, whereas cefoperazone (MIC50 > 64 ,ug/ml) demonstrated less activity. The MIC50 and MIC90 for each genus tested are shown in Table 1 . Against E. coli, amifloxacin, norfloxacin, moxalactam, and cefotaxime were as a group more active than the other agents tested. For the gentamicinresistant E. coli strains, sulfamethoxazole-trimethoprim, interestingly, had very little activity. For Klebsiella pneumoniae and Enterobacter species, amifloxacin and norfloxacin were most active, whereas cefotaxime and moxalactam showed less activity than they showed against E. coli. For Serratia marcescens amifloxacin and norfloxacin had higher MIC90s than those for the above strains, followed closely by cefotaxime and moxalactam. Cefoperazone was much less active, whereas amikacin had intermediate activity. For Acinetobacter species, amifloxacin was clearly different in its increased activity (MIC90 = 8 jig/ml) compared with that of the other agents. For P. aeruginosa, also, amifloxacin (MIC90 = 16 p.g/ml) and norfloxacin (MIC90 = 8 ,ug/ml) were by far the most active agents.
Additional MICs and MBCs of amifloxacin were determined for 17 strains by using a serial twofold dilution (Table  2 ). For only one Enterobacter strain and one P. aeruginosa strain tested was the MBC greater than one dilution above the MIC. Otherwise, amifloxacin showed excellent bactericidal activity.
Amifloxacin is one of several new quinolone antimicrobial agents which demonstrate increased activity over the progenitor of the class, nalidixic acid (5). Nalidixic acid, along with oxolinic acid, is known to inhibit a subunit of E. coli gyrase (topoisomerase A) which promotes the DNA nickclosing function (13) . Conversely, the other gyrase subunit (topoisomerase B), which promotes incorporation of ATP into twisted DNA, is inhibited by novobiocin and coumermycin (9) . Thus, quinolones inhibit bacterial cells at an early stage of replication and inhibit plasmid replication as well (6) 
